↓ Skip to main content

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

Overview of attention for article published in Clinical Rheumatology, August 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
1 news outlet
twitter
5 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
42 Mendeley
Title
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Published in
Clinical Rheumatology, August 2019
DOI 10.1007/s10067-019-04679-y
Pubmed ID
Authors

Christopher J. Edwards, Joëlle Monnet, Martin Ullmann, Pantelis Vlachos, Veranika Chyrok, Vishal Ghori

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Other 6 14%
Researcher 5 12%
Student > Master 4 10%
Student > Doctoral Student 3 7%
Student > Bachelor 2 5%
Other 5 12%
Unknown 17 40%
Readers by discipline Count As %
Medicine and Dentistry 17 40%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Linguistics 1 2%
Computer Science 1 2%
Agricultural and Biological Sciences 1 2%
Other 0 0%
Unknown 18 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2019.
All research outputs
#2,756,102
of 23,153,849 outputs
Outputs from Clinical Rheumatology
#360
of 3,057 outputs
Outputs of similar age
#58,212
of 345,020 outputs
Outputs of similar age from Clinical Rheumatology
#14
of 80 outputs
Altmetric has tracked 23,153,849 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,057 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,020 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.